bioRxiv · 10.1101/2020.04.09.033233
Structural basis for the inhibition of COVID-19 virus main protease by carmofur, an antineoplastic drug
Abstract
The antineoplastic drug Carmofur was shown to inhibit SARS-CoV-2 main protease (Mpro). Here the X-ray crystal structure of Mpro in complex with Carmofur reveals that the carbonyl reactive group of Carmofur is covalently bound to catalytic Cys145, whereas its fatty acid tail occupies the hydrophobic S2 subsite. Carmofur inhibits viral replication in cells (EC50 = 24.30 M) and it is a promising lead compound to develop new antiviral treatment for COVID-19.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Jin, Z., Zhao, Y., Sun, Y., Zhang, B., Wang, H., Wu, Y., Zhu, Y., Zhu, C., Hu, T., Du, X., Duan, Y., Yu, J., Yang, X., Liu, X., Guddat, L. W., Xiao, G., Zhang, L., Yang, H., Rao, Z.. 2020-04-09. Structural basis for the inhibition of COVID-19 virus main protease by carmofur, an antineoplastic drug. https://doi.org/10.1101/2020.04.09.033233
Cite the original work for its findings. Save a collection to share your selection of sources.